Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Income from Continuing Operations (2019 - 2023)

Alx Oncology Holdings' Income from Continuing Operations history spans 5 years, with the latest figure at 91066000.0 for Q4 2023.

  • For Q4 2023, Income from Continuing Operations rose 397.18% year-over-year to 91066000.0; the TTM value through Dec 2023 reached 24685000.0, up 80.0%, while the annual FY2025 figure was 497000.0, 99.63% up from the prior year.
  • Income from Continuing Operations for Q4 2023 was 91066000.0 at Alx Oncology Holdings, up from 50989000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 91066000.0 in Q4 2023 and bottomed at 50989000.0 in Q3 2023.
  • The 5-year median for Income from Continuing Operations is 15229500.0 (2021), against an average of 12342333.33.
  • The largest annual shift saw Income from Continuing Operations crashed 235.34% in 2020 before it surged 397.18% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 3036000.0 in 2019, then plummeted by 206.88% to 9317000.0 in 2020, then surged by 362.53% to 24460000.0 in 2021, then plummeted by 225.28% to 30643000.0 in 2022, then soared by 397.18% to 91066000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Income from Continuing Operations are 91066000.0 (Q4 2023), 50989000.0 (Q3 2023), and 34483000.0 (Q2 2023).